The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data

* OASIS 1 and 2 studies demonstrated positive results for investigational compound elinzanetant which met all primary endpoints by significantly reducing frequency and severity of moderate to severe vasomotor symptoms [...]